Table 4 Significant effects of poly-miRTS on chemotherapy response in AML patients by Univariate and Logistic regression analysis
Genotype | Total (N) | CR, N (%) | P | OR (95% CI) | P a | OR (95% CI)a |
|---|---|---|---|---|---|---|
rs3811810 | ||||||
 GG | 167 | 138 (82.6) |  | 1.00 (reference) |  | 1.00 (reference) |
 AA | 3 | 3 (100) | 0.999 | – |  | – |
 GA | 36 | 35 (97.2) | 0.054 | 7.355 (0.968–55.873) | 0.070 | 6.671 (0.854–52.098) |
 AA+GAb | 39 | 38 (97.4) | 0.044 | 7.986 (1.053–60.532) | 0.058 | 7.258 (0.934–56.388) |
rs7278 | ||||||
 CC | 165 | 136 (82.4) |  | 1.00 (reference) |  | 1.00 (reference) |
 TT | 4 | 4 (100) | 0.999 | – |  | – |
 TC | 37 | 36 (97.3) | 0.049 | 7.676 (1.011–58.276) | 0.053 | 7.588 (0.971–59.319) |
 TT+TCb | 41 | 40 (97.6) | 0.038 | 8.529 (1.127–64.581) | 0.040 | 8.572 (1.106–66.423) |
rs1042919 | ||||||
 TT | 109 | 101 (92.7) |  | 1.00 (reference) |  | 1.00 (reference) |
 AA | 9 | 7 (77.8) | 0.146 | 0.277 (0.049–1.561) | 0.060 | 0.165 (0.025–1.078) |
 AT | 88 | 68 (77.3) | 0.003 | 0.269 (0.112–0.646) | 0.003 | 0.253 (0.102–0.630) |
 AA+ATb | 97 | 75 (77.3) | 0.003 | 0.270 (0.114–0.640) | 0.002 | 0.246 (0.100–0.604) |
rs3734703 | ||||||
 CC | 122 | 108 (88.5) |  | 1.00 (reference) |  | 1.00 (reference) |
 AA | 17 | 16 (94.1) | 0.495 | 2.074 (0.255–16.863) | 0.495 | 2.097 (0.249–17.630) |
 CA | 67 | 52 (77.6) | 0.050 | 0.449 (0.202–1.000) | 0.066 | 0.455 (0.197–1.054) |
 CC+AA/CAc | 139 | 124 (89.2) | 0.030 | 2.385 (1.087–5.231) | 0.023 | 2.561 (1.136–5.775) |